Drugs online research references
Paroxetine in the treatment of premature ejaculation.
The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat.
Liposomes bearing platelet proteins: a model for surface functions studies.
Programming of brainstem serotonin transporter development by prenatal glucocorticoids.
Synthesis and transporter binding properties of 3 beta-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2 beta-carboxylic acid methyl esters: serotonin transporter selective analogs.
Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using 3Hparoxetine.
High-affinity binding of 3Hparoxetine to caudate nucleus and microvessels from porcine brain.
Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model.
Pharmacological characterization of BNMPA (alpha-benzyl-N-methylphenethylamine), an impurity of illicit methamphetamine synthesis.
Efficacy and tolerability of paroxetine in the treatment of the depressive phase of bipolar disorders
Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity.
Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse.
Sleep-related painful erections: clinical and polysomnographic features.
The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice.
Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.
The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine.
Protective effect of citalopram against the attenuation of the alpha 1-potentiation of cAMP formation in Fischer 344 strain rats.
Regional distribution of specific high affinity binding sites for 3H-imipramine and 3H-paroxetine in human brain.
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection.
Efficacy of paroxetine for the treatment of depression in the context of HIV infection.
Serotonergic aspects of the response of human platelets to immune-adjuvant muramyl dipeptide.
Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
Substitution of the selective serotonin reuptake inhibitors fluoxetine and paroxetine for the discriminative stimulus effects of ethanol in rats.
Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors.
Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder.
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
The degree of inhibition of dopaminergic neurons in the ventral tegmental area induced by selective serotonin reuptake inhibitors is a function of the density-power-spectrum of the interspike interval.
Radiosynthesis and PET imaging of N-methyl-11CLY257327 as a tracer for 5-HT transporters.
Chronic paroxetine desensitises 5-HT1D but not 5-HT1B autoreceptors in rat lateral geniculate nucleus.
Polarized expression of the antidepressant-sensitive serotonin transporter in epinephrine-synthesizing chromaffin cells of the rat adrenal gland.
Paroxetine increases heart rate variability in panic disorder.
5-HT3 receptor-active drugs alter development of spinal serotonergic innervation: lack of effect of other serotonergic agents.
Effects of repeated selective serotonin reuptake inhibitor paroxetine treatments on mouse forced swimming.
Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
Inhibition by nitric oxide of the uptake of 3Hserotonin into rat brain synaptosomes.
2'-Substitution of cocaine selectively enhances dopamine and norepinephrine transporter binding.
Specific neurochemical derangements of brain projecting neurons in apolipoprotein E-deficient mice.
Synthesis and ligand binding of tropane ring analogues of paroxetine.
Enhanced displacement of 3Himipramine, but not 3Hparoxetine binding by plasma from depressed patients.
Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory.
Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential.
Serotonergic projections to the retina of rat and goldfish.
Synthesis and 5-HT receptors binding studies of some 3-substituted-2-(4-methyl-1-piperazinyl)-4-phenylquinolines.
Effects of washing procedure on platelets pretreated with serotonin uptake inhibitors in vitro: low Ki values predict long-lasting inhibition of serotonin uptake in vivo.
The SSRI antidepressants: exploring their "other" possible properties.
Presence and characterization of the serotonin transporter in human resting lymphocytes.
Platelet serotonergic functions and light therapy in seasonal affective disorder.
Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline.
The serotonin syndrome scale: first results on validity.
The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Peripheral markers of serotonergic and noradrenergic function in post-pubertal, caucasian males with autistic disorder.
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Paroxetine for pruritus in advanced cancer.
Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma.
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy').
Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.
Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Concomitant therapy with anxiolytics or hypnotics and maintenance of initial SSRI therapy.
Citalopram elicits a discriminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs. dopamine and noradrenaline.
Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain.
Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test.
Prolonged stationary colonic motility recording in seven patients with severe constipation secondary to antidepressants.
Improved synthesis of paroxetine hydrochloride propan-2-ol solvate through one of metabolites in humans, and characterization of the solvate crystals.
Effect of 3,4-methylenedioxymethamphetamine on 3Hparoxetine binding in the frontal cortex and blood platelets of rats.
Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain.
Paroxetine binding to the rat norepinephrine transporter in vivo.
Newer antidepressants: a comparison of tolerability in general practice.
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people.
Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine.
Serotonin reuptake is less efficient in taste aversion resistant than in taste aversion-prone rats.
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Potentiation by (-)Pindolol of the activation of postsynaptic 5-HT(1A) receptors induced by venlafaxine.
Radiosynthesis and evaluation of N-(3-18Ffluoropropyl)paroxetine as a radiotracer for in vivo labeling of serotonin uptake sites by PET.
Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil.
Platelet reactivity in depressed patients treated with paroxetine: preliminary findings.
The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia.
Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine.
Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release.
The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome.
Chronic prenatal exposure to paroxetine (Paxil) and cognitive development of mice offspring.
Effect of paroxetine on plasma vasopressin and water load testing in elderly individuals.
5-HT1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex.
The toxicity profile of a single dose of paroxetine: an alternative approach to acute toxicity testing in the rat.
Modulation of 3Hparoxetine binding to the 5-hydroxytryptamine uptake site in an animal model of depression.
An ideal trial to test differential onset of antidepressant effect.
Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation.
Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction.
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.
Changes in intake pattern in obese patients treated with paroxetine
Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies.
Rx drugs
Mood disorders in children and adolescents: psychopharmacological treatment.
Ethanol intake and 3H-serotonin uptake. II: A study in alcoholic patients using platelets 3H-paroxetine binding.
Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?
Determination of moclobemide, paroxetine, and fluvoxamine in tablets by HPLC.
The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Alterations in serotonin transporter expression in brain regions of rats exposed neonatally to chlorpyrifos.
Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Rx drugs
The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue.
Clinical characteristics and psychotropic therapy of depressive and anxious symptoms of patients with somatic diseases
Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons.
Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using 3H-quipazine and 3H-GR65630 binding.
Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors.
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life.
Sertralilne, paroxetine and venlafaxine in refugee post traumatic stress disorder with depression symptoms.
Evaluating the tolerability of the newer antidepressants.
Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.
Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.
Rx drugs
The selective serotonin re-uptake inhibitors fluvoxamine and paroxetine differ in sexual inhibitory effects after chronic treatment.
Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.
Rx drugs
Diurnal variation in 5-HT1B autoreceptor function in the anterior hypothalamus in vivo: effect of chronic antidepressant drug treatment.
Evidence for the existence of serotonin uptake inhibitor-like substances in human cerebrospinal fluid.
Rx drugs
Differential effects of chronic antidepressant treatments on micro- and delta-opioid receptors in rat brain.
Paroxetine and its uses in psychiatry.
Regulation of the platelet serotonin transporter by protein kinase C in the young and elderly.
Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
Neuropsychological profile in patients with obsessive-compulsive disorder over a period of 4-month treatment.
Ionic interactions in the Drosophila serotonin transporter identify it as a serotonin channel.
Morphine, cocaine and antidepressant induced motivational activity and midbrain dopaminergic neurotransmission.
MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities.
Perinatal outcome following third trimester exposure to paroxetine.
3H-paroxetine binding in brains of alcoholics.
Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine.
A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation.
Paradoxical effects of serotonin and opioids in pemoline-induced self-injurious behavior.
Serotonin in the developing stomatogastric system of the lobster, Homarus americanus.
Feeding and reward interactions from chronic paroxetine treatment.
Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells.
Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation.
State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine.
Proofs of efficacy
Neurobiology and genetics of anxiety in an animal model
Pharmacokinetics of paroxetine in patients with cirrhosis.
Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity.
Anxiety induced by repetitive transcranial magnetic stimulation is suppressed by chronic treatment of paroxetine in rats.
Effects of Hypericum perforatum and paroxetine in the mouse defense test battery.
Anhydrides as acylating agents in the enzymatic resolution of an intermediate of (-)-Paroxetine.
Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain.
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Quantitative electroencephalography in OCD patients treated with paroxetine.
Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies.
Rx drugs
Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression.
Laminar distributions of muscarinic acetylcholine, serotonin, GABA and opioid receptors in human posterior cingulate cortex.
Antidepressant-like effects in various mice strains in the tail suspension test.
Platelet paroxetine binding in alcoholics.
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
Brain neurosteroid changes after paroxetine administration in mice.
Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1.
3Hparoxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment.
Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
123/125IRTI-55, an in vivo label for the serotonin transporter.
The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.
Role of essential sulfhydryl groups in drug interactions at the neuronal 5-HT transporter. Differences between amphetamines and 5-HT uptake inhibitors.
Antidepressant binding sites in brain: autoradiographic comparison of 3Hparoxetine and 3Himipramine localization and relationship to serotonin transporter.
Partial purification and characterization of the sodium-ion-coupled 5-hydroxytryptamine transporter of rat cerebral cortex.
Cellular localization of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat.
Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat.
Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography.
Interaction of fluoxetine with the human placental serotonin transporter.
3Hparoxetine binding in human platelets in relation to age and sex.
The advantages of paroxetine in different subgroups of depression.
Brain 5-HT uptake sites, labelled with 3Hparoxetine, in antidepressant-free depressed suicides.
Why some depressed patients may have low platelet 3H-imipramine binding.
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
High affinity 3Hparoxetine binding to serotonin uptake sites in human brain tissue.
Differences in the temperature dependence of drug interaction with the noradrenaline and serotonin transporters.
Behavioral pharmacological properties of the novel antidepressant paroxetine, a selective 5-HT uptake inhibitor
A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
Effect of 5-hydroxytryptamine on 3H-acetylcholine release from guinea-pig striatal slices.
Repeated electroconvulsive shock does not change 3H-paroxetine binding to the 5-HT uptake site in rat cortical membranes.
The activity of 25 paroxetine/femoxetine structure variants in various reactions, assumed to be important for the effect of antidepressants.
Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.
Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats.
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes.
Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on 3Hparoxetine binding to cerebral cortical membranes of the rat.
Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine on EEG sleep and waking stages in the rat.
Regional and subcellular localization in human brain of 3Hparoxetine binding, a marker of serotonin uptake sites.
Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.
Measuring the serotonin uptake site using 3Hparoxetine--a new serotonin uptake inhibitor.
Pitfalls in demonstrating an endogenous ligand of imipramine recognition sites.
A comparison of the effect of paroxetine and amitriptyline on the tyramine pressor response test.
Rx drugs
Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.
Imipramine binding site. Temperature dependence of the binding of 3H-labeled imipramine and 3H-labeled paroxetine to human platelet membrane.
Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.
Synthesis and characterization of an aryl-azidoparoxetine. A novel photo-affinity probe for serotonin-transporter.
Lack of circadian variation in the responsiveness of alpha 2-heteroreceptors regulating serotonin release.
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones.
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice.
Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine.
3H cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine.
Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder.
Autoradiographic characterization of binding sites for 3Hmilnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain.
Platelet 3Hparoxetine binding in panic disorder.
Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine
Platelet serotonin markers and depressive symptomatology.
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning.
Differential effects of 5,7-dihydroxytryptamine-induced serotoninergic degeneration of 5-HT1A receptors and 5-HT uptake sites in the rat brain.
Anxiolytic-like effect of paroxetine in a rat social interaction test.
Binding potency of 6-nitroquipazine analogues for the 5-hydroxytryptamine reuptake complex.
3Hparoxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia.
Paroxetine: new indication. In generalised anxiety: uncertain efficacy.
3Hparoxetine and 3Hcitalopram as markers of the human brain 5-HT uptake site: a comparison study.
What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
Further studies on platelet serotonin transporter binding in depression.
Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography.
Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors.
Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome.
Influence of the dorsal and median raphe nuclei on neurons in the periaqueductal gray matter: role of 5-hydroxytryptamine.
Platelet serotonin measures in primary dysthymia.
Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity.
Tolerance to the anorectic effect of dexfenfluramine in rats: role of serotonin, cholecystokinin, and neuropeptide Y.
alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics.
Comparison of the effects of tianeptine and paroxetine on amnesic deficits induced by prolonged alcohol drinking in mice
Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.
Pharmacogenetics of cocaine: II. Mesocorticolimbic and striatal dopamine and cocaine receptors in C57BL and DBA mice.
Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
Platelet paroxetine binding and light therapy in winter depression.
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neurotransmission.
Further evidence for the existence of endogenous serotonin uptake inhibitors and their purification by calmodulin affinity chromatography.
Paroxetine binding in the blood platelets of post-traumatic stress disorder patients.
125I5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. I. In vitro studies.
The regeneration of d,l-fenfluramine-destroyed serotonergic nerve terminals.
Increased cholesterol levels during paroxetine administration in healthy men.
A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.
Autoradiographic analyses of the effects of estradiol benzoate on 3Hparoxetine binding in the cerebral cortex and dorsal hippocampus of gonadectomized male and female rats.
Central serotonergic uptake mechanisms in hypertensive rats: effects of clonidine and centhaquin.
Aging and 3H-paroxetine binding in rat brain: effect of imipramine and tetrahydroacridine.
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones.
Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder.
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Long-lasting inhibition of 5-HT uptake of platelets in subjects treated by duloxetine, a potential antidepressant.
Synthesis of 3 beta-aryl-8-azabicyclo3.2.1octanes with high binding affinities and selectivities for the serotonin transporter site.
Effects of paroxetine on 5-HT-induced head twitches and phosphatidylinositol hydrolysis in mice.
DreamPharm: Herbal and Nutritional supplements online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||